Trial Profile
An exploratory study to evaluate the immune restoration after removal of viral antigen in patients with chronic hepatitis C virus treated with ombitasvir/oparitaprevir/ ritonavir + dasabuvir and ribavirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Jul 2017 New trial record